Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DORZOLAMIDE HYDROCHLORIDE vs ANEXSIA 7.5/650
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dorzolamide hydrochloride is a carbonic anhydrase II inhibitor. By inhibiting carbonic anhydrase in the ciliary processes of the eye, it reduces aqueous humor secretion, thereby lowering intraocular pressure.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma,Adjunctive therapy with beta-blockers in patients with open-angle glaucoma or ocular hypertension
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
One drop of 2% solution in the affected eye(s) three times daily.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
Terminal elimination half-life is approximately 4 months for red blood cell carbonic anhydrase II binding; systemic half-life of free drug is about 3-4 hours.
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Dorzolamide is metabolized primarily by hepatic cytochrome P450 enzymes, specifically CYP2C9, to N-desethyl-dorzolamide. It forms N-acetylated metabolites as well as the N-desethyl metabolite. Minor renal elimination of unchanged drug occurs.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Renal: approximately 70% of a topically applied dose is excreted unchanged in urine over 120 hours; <2% fecal.
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Approximately 33% bound to plasma proteins, primarily albumin.
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
Wide distribution: apparent Vd is approximately 0.53 L/kg; extensive binding to carbonic anhydrase in red blood cells and tissues.
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Topical ophthalmic: systemic absorption is minimal (approximately 2-4% of administered dose reaches systemic circulation due to nasolacrimal drainage and ocular absorption).
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild to moderate impairment; use with caution.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
No specific dose adjustment required based on Child-Pugh classification; however, use with caution in severe hepatic impairment due to potential for systemic accumulation.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Safety and efficacy not established in pediatric patients. No standard weight-based dosing guidelines available. Some sources recommend the same adult dose (one drop of 2% solution three times daily) for children aged ≥2 years; use with caution.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
No specific dose adjustment required, but elderly patients may be more susceptible to systemic effects; monitor for ocular irritation and electrolyte imbalance.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
None
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
Sulfonamide hypersensitivity: Dorzolamide is a sulfonamide derivative; cross-reactivity may occur. Discontinue if signs of serious hypersensitivity reactions develop.,Corneal edema and endothelial decompensation: Use with caution in patients with compromised corneas (e.g., low endothelial cell count).,Ocular effects: Transient blurred vision, burning, stinging, and superficial punctate keratitis may occur.,Potential for metabolic acidosis: Carbonic anhydrase inhibitors can cause metabolic acidosis; use with caution in patients with renal impairment or those on concomitant topiramate or acetazolamide.,Bacterial keratitis: Risk with contaminated multidose containers.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Hypersensitivity to dorzolamide hydrochloride or any component of the formulation,Severe renal impairment (creatinine clearance < 30 m L/min),Hyperchloremic acidosis
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
None known. No dietary restrictions are required with topical dorzolamide use.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
Dorzolamide is a carbonic anhydrase inhibitor. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2.5 mg/kg/day (rabbit) and 20 mg/kg/day (rat). Low systemic absorption (≈4% of ocular dose) minimizes fetal exposure. FDA Pregnancy Category C. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. No specific trimester risks.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
It is not known whether dorzolamide is excreted in human milk. Systemic absorption is low (≈4%). Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. M/P ratio not available. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for dorzolamide and potential adverse effects on the breastfed child.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
No dose adjustment is recommended. The systemic absorption of topical dorzolamide is low (≈4%) and pharmacokinetics are not expected to change significantly in pregnancy. Use the standard adult dose: one drop in the affected eye(s) three times daily.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
Dorzolamide is a topical carbonic anhydrase inhibitor used for elevated intraocular pressure. It can cause metabolic acidosis due to systemic absorption, especially in patients with renal impairment. Avoid use with oral carbonic anhydrase inhibitors to prevent additive systemic effects. Monitor for corneal edema in patients with compromised corneas. The drug may cause transient blurred vision; apply pressure over the nasolacrimal duct to minimize systemic absorption.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Instill one drop in the affected eye(s) three times daily, as directed.,Wash hands before and after use. Avoid touching the dropper tip to any surface.,If using other eye drops, wait at least 5 minutes between administrations.,Do not wear contact lenses during treatment; may discolor soft contact lenses.,Report eye pain, redness, vision changes, or signs of allergy (rash, itching).,May cause temporary blurred vision; do not drive or operate machinery until vision clears.,Store at room temperature, tightly closed, and protect from light.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
"Dorzolamide, a carbonic anhydrase inhibitor used for glaucoma, may theoretically inhibit the metabolism of cobicistat, a pharmacokinetic enhancer used in HIV therapy, by competing for hepatic CYP3A4 enzymes or altering renal clearance. This interaction could lead to increased cobicistat exposure, potentiating its adverse effects such as nephrotoxicity or gastrointestinal disturbances. However, clinically relevant interactions are unlikely due to dorzolamide's limited systemic absorption following ophthalmic administration."
"Chlorthalidone, a thiazide-like diuretic, and dorzolamide, a carbonic anhydrase inhibitor, both act to reduce bicarbonate reabsorption in the kidney, leading to enhanced electrolyte excretion, particularly potassium and bicarbonate. This synergistic effect can cause additive hypokalemia and metabolic acidosis, increasing the risk of cardiac arrhythmias and renal dysfunction. Concurrent use may also potentiate hypotensive effects due to volume depletion and vasodilation."
"Concurrent administration of dorzolamide, a carbonic anhydrase inhibitor, may reduce the urinary acidification necessary for methenamine's conversion to formaldehyde, the active antibacterial agent. This alkalinization of urine pH impairs the therapeutic efficacy of methenamine in treating urinary tract infections. Clinically, this can result in suboptimal bactericidal activity and potential treatment failure."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DORZOLAMIDE HYDROCHLORIDE vs ANEXSIA 7.5/650, answered by our medical review team.
DORZOLAMIDE HYDROCHLORIDE is a Carbonic Anhydrase Inhibitor that works by Dorzolamide hydrochloride is a carbonic anhydrase II inhibitor. By inhibiting carbonic anhydrase in the ciliary processes of the eye, it reduces aqueous humor secretion, thereby lowering intraocular pressure.. ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DORZOLAMIDE HYDROCHLORIDE and ANEXSIA 7.5/650 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DORZOLAMIDE HYDROCHLORIDE is: One drop of 2% solution in the affected eye(s) three times daily.. The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DORZOLAMIDE HYDROCHLORIDE and ANEXSIA 7.5/650 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DORZOLAMIDE HYDROCHLORIDE is classified as Category C. Dorzolamide is a carbonic anhydrase inhibitor. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2.5 mg/kg/day (ra. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.